




# SUVEN PHARMA

Earnings Presentation  
Q4 & FY21





# Risk Statement

---

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Seven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Seven may not undertake to update any forward-looking statements that may be made from time to time.



# Table of Contents

4

**Operation &  
Financial  
Performance Q4 &  
FY21**




11

**Company  
Background**

# Operation & Financial Performance FY21

---

# Businesswise data



**Note:** Figures in Rs. Crore

# Financial Snapshot

FY21

Growth in  
**Revenue**



Growth in  
**EBITDA**




Growth in  
**PAT**




# Key Ratios

FY21


**EBIT** to  
Income







**EBITDA** to  
Income





**PAT** to  
Income



# Financials FY21



# Financials FY21



# Financial Table – Q4 & FY21

	Quarter ended			Year ended	
	31-Mar-21	31-Dec-20	31-Mar-20	31-Mar-21	31-Mar-20
Revenue	2,624.63	2,797.76	1,901.05	10,239.56	8,519.07
EBITDA	969.91	1,421.77	819.16	4,547.59	3,997.60
EBITDA Margin	36.95%	50.82%	43.09%	44.41%	46.93%
EBIT	886.76	1,334.20	749.52	4,231.23	3,762.53
EBIT Margin	33.79%	47.69%	39.43%	41.32%	44.17%
Finance costs	18.70	19.10	65.12	91.44	186.62
Depreciation	83.15	87.58	69.64	316.36	235.07
Taxes	223.54	338.75	151.99	1,053.32	875.10
Taxes to PBT	25.75%	25.76%	22.21%	25.44%	24.47%
PAT (Standalone)	644.52	976.35	532.41	3,086.47	2,700.80
PAT Margin (Standalone)	24.56%	34.90%	28.01%	30.14%	31.70%
Unrealised Share of Profit of Associate Company	186.66	160.00	209.69	537.36	482.13
PAT (Consolidated)	831.16	1,136.25	741.82	3,623.42	3,170.02
PAT Margin (Consolidated)	31.67%	40.61%	39.02%	35.39%	37.21%
EPS (Standalore)	2.53	3.84	2.09	12.12	10.61
EPS (Consolidated)	3.27	4.46	2.91	14.23	12.45
Paid up share capital (Re.1/sh)	254.56	254.56	127.28	254.56	127.28

*All figures are in INR Million, other than ratios and EPS*

# Company Background

---

# Business Model



# Brief Profile

## BUSINESS OVERVIEW

- Integrated CDMO company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing.

## KEY STRENGTHS

- Preferred global outsourcing partner with capabilities across the entire CDMO value chain.
- Strong chemistry skills.

## FINANCIAL OVERVIEW

- Consolidated Revenues, EBITDA and Adj. PAT of Rs 2625 Mn, Rs 970 Mn and Rs 831 Mn in Q4-FY21.
- Consolidated Revenues, EBITDA and Adj. PAT of Rs. 10240 Mn, Rs. 4548 Mn and Rs. 3623 Mn for the year ending 2021.
- Strong balance sheet with D:E ratio of 0.03 as on Mar-21.

Suven is an integrated Contract Development and Manufacturing Operations company

Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations.

Since our founding in 1989 (pre-demerger), Suven has established its core competency in cyanation and heterocyclic chemistry, including pyrimidines, quinolones, thiazoles, and imidazoles, in addition to demonstrating our proficiency in Carbohydrate and Chiral chemistry including tetrahydrofurans, amino acids and sulfoxides from gram to multi-ton scale.

Suven effectively uses its expanding infrastructure and ability to collaborate, from route scouting and development through commercial manufacture, to provide a consistent and reliable partner throughout a product's life cycle.

Suven is dedicated to going beyond commitment and delivering R&D and Manufacturing solutions, with flexibility, quality, speed, and cost effectiveness.

---

## Our Focus

---

**A full-fledged bio-pharmaceutical solutions provider for global pharmaceutical companies**




**NCE based  
CDMO**

# Financial Approach




# Business Drivers

## Industry Relationship



# Business Drivers

## Execution Capabilities



# Multi Location Facilities

**Vizag, Andhra Pradesh, India**



- 307 KL reactor volume
- 3KL to 12KL Reactors
- GL/SS (45No's)
- API's/Advanced Intermediate's/CMO

**Pashamylaram, Telangana, India  
API & Formulation Facility**



- 120 kL reaction volume
- 50L – 6000 L GL/SS (45)
- API Manufacturing
- Formulation R&D

**Banjara Hills, Hyderabad, India  
Corporate Office**



- Process Research
- Discovery R&D, Analytical R&D
- Killo lab, 30L CM Reactors (32)
- 50L – 4000 L GL/SS

**Jeedimetla, Telangana, India  
R&D–Pilot Plant**



**Suryapet, Telangana, India  
Intermediate Mfg. Facility**



- Business Development
- Project Management
- Intellectual Property Management

**USA, New Jersey  
Business Office**



- 300 CM reactors (93)
- 500L to 10 KL GL/SS
- GMP Intermediates

# Contact

## Suven Pharmaceuticals Ltd

# 8-2-334, SDE Serene Chambers,  
3rd Floor, Road No. 5, Avenue - 7, Banjara  
Hills, Hyderabad-500 034, Telangana, INDIA.  
+91-40-2354-9414 /1142 /3311

**For queries and requests, please  
contact:**

**Suven Pharmaceuticals Ltd**

**Email:** [info@suvenpharm.com](mailto:info@suvenpharm.com)

**For more info:** [www.suvenpharm.com](http://www.suvenpharm.com)

Gavin Desa / Rishab Barar

**CDR - India**

**Tel:** +91 22 6645 1237 / 1235

**Email:** [gavin@cdr-india.com](mailto:gavin@cdr-india.com)  
[rishab@cdr-india.com](mailto:rishab@cdr-india.com)



Thank You

